Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study

Neurotherapeutics

Volumn 13, Issue 4, 2016, Pages 824-832

  Lee, Woo Jin ^a,b   Lee, Soon Tae ^a,b   Moon, Jangsup ^a,b   Sunwoo, Jun Sang ^a,b   Byun, Jung Ick ^a,b   Lim, Jung Ah ^a,b   Kim, Tae Joon ^a,b   Shin, Yong Won ^a,b   Lee, Keon Joo ^a,b   Jun, Jin Sun ^a,b   Lee, Han Sang ^a,b   Kim, Soyun ^a   Park, Kyung Il ^a,c   Jung, Keun Hwa ^a,b   Jung, Ki Young ^a,b   Kim, Manho ^a,b   Lee, Sang Kun ^a,b   Chu, Kon ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Hospital Healthcare System Gangnam Center   (South Korea)

Author keywords

Autoimmune disorders; encephalitis; immunotherapy; prognosis; tocilizumab

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PARACETAMOL; RITUXIMAB; TOCILIZUMAB; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ALLERGIC ENCEPHALITIS; ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; RANKIN SCALE; RASH; RETROSPECTIVE STUDY; ADOLESCENT; AGED; CHILD; ENCEPHALITIS; HASHIMOTO DISEASE; MIDDLE AGED; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; ENCEPHALITIS; FEMALE; HASHIMOTO DISEASE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RITUXIMAB; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84969884909     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-016-0442-6     Document Type: Article

References (37)

1. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011;77:179-189.
2. Zuliani L, Graus F, Giometto B, Bien C, Vincent A. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry 2012:jnnp-2011-301237.
3. Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 2012;54:899-904.
4. Armangue T, Leypoldt F, Dalmau J. Autoimmune encephalitis as differential diagnosis of infectious encephalitis. Curr Opin Neurol 2014;27:361-368.
5. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15:391-404.
6. Singh TD, Fugate JE, Rabinstein AA. The spectrum of acute encephalitis causes, management, and predictors of outcome. Neurology 2015;84:359-366.
7. Hacohen Y, Wright S, Waters P, et al. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry 2013;84:748-755.
8. Lee W-J, Lee S-T, Byun J-I, et al. Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. Neurology 2016:10.1212/WNL. 0000000000002635.
9. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157-165.
10. Kim SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica 2010;95:1935-1942.
11. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma—a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:1088-1095.
12. Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett 2011;585:3699-3709.
13. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988;141:1543-1549.
14. Kimura A, Kishimoto T. IL-6: Regulator of Treg/Th17 balance. Eur J Immunol 2010;40:1830-1835.
15. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 2005;23:1-21.
16. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-997.
17. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68:1580-1584.
18. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010;62:542-552.
19. Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica A pilot study. Neurology 2014;82:1302-1306.
20. Ayzenberg I, Kleiter I, Schröder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 2013;70:394-397.
21. Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term Therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol 2015;72:756-763.
22. Krogias C, Hoepner R, Müller A, Schneider-Gold C, Schröder A, Gold R. Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab. JAMA Neurol 2013;70:1056-1059.
23. Irani SR, Vincent A. Targeting the interleukin 6 receptor to treat neuromyelitis optica. JAMA Neurol 2015;72:747-748.
24. Venkatesan A, Tunkel A, Bloch K, et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis 2013;57:1114-1128.
25. Kim T-J, Lee S-T, Shin J-W, et al. Clinical manifestations and outcomes of the treatment of patients with GABA B encephalitis. J Neuroimmunol 2014;270:45-50.
26. Lim J-A, Lee S-T, Jung K-H, et al. Anti-N-methyl-d-aspartate receptor encephalitis in Korea: clinical features, treatment, and outcome. J Clin Neurol 2014;10:157-161.
27. Sunwoo J-S, Lee S-T, Byun J-I, et al. Clinical manifestations of patients with CASPR2 antibodies. J Neuroimmunol 2015;281:17-22.
28. Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008;47:303-327.
29. Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009;9:10-25.
30. Common Terminology Criteria for Adverse Events (CTCAE v4.0). Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_403_2010-06-14_QuickReference_5x7.pdf. Accessed April 1, 2015.
31. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 2014;83:142-150.
32. Ogura H, Murakami M, Okuyama Y, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008;29:628-636.
33. Gijbels K, van Damme J, Proost P, Put W, Carton H, Billiau A. Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis. Eur J Immunol 1990;20:233-235.
34. Gruol D, Nelson T. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 1997;15:307-339.
35. Irani SR, Gelfand JM, Al-Diwani A, Vincent A. Cell-surface central nervous system autoantibodies: Clinical relevance and emerging paradigms. Ann Neurol 2014;76:168-184.
36. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
37. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815.